Skip to main content

Search

Show all results for

Home

Person

Anne-Laure Mahul Mellier

About
Privacy
Disclaimer

Copyright © 2025 EPFL, all rights reserved

Graph Chatbot

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related units (1)

Prof. D'Angelo Group

EPFL
SV
IBI-SV
UPDANGELO

Courses taught by this person (2)

BIO-480: Neuroscience: from molecular mechanisms to disease

The goal of the course is to guide students through the essential aspects of molecular neuroscience and neurodegenerative diseases. The student will gain the ability to dissect the molecular basis of

BIOENG-430: Selected topics in life sciences

The course presents an overview on how recent advances at the interfaces of biology, biotechnology, engineering, physical sciences, and medicine are 1) shaping the landscape of biomedical research; 2)

Related publications (14)

Please note that this is not a complete list of this person’s publications. It includes only semantically relevant works. For a full list, please refer to Infoscience.

Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation

Graham Knott, Romain Hamelin, Anne-Laure Mahul Mellier, Nadine Aït Bouziad, Jonathan Jean-Pierre Ricci, Yllza Jasiqi, Mary-Claude Croisier-Coeytaux, Anass Chiki, Melek Firat Altay, Somanath Jagannath

Alpha-synuclein (aSyn) post-translational modifications (PTM), especially phosphorylation at serine 129 and C-terminal truncations, are highly enriched in Lewy bodies (LB), Lewy neurites, and other pathological aggregates in Parkinson's disease and synucle ...

Springer Science and Business Media LLC2025

Emerging disease-modifying therapies for Parkinson’s disease Nouvelles stratégies thérapeutiques dans la maladie de Parkinson

Anne-Laure Mahul Mellier

Despite extensive clinical research, no disease-modifying treatment has been proven to alter the progression of Parkinson’s disease (PD). However, recent decades have seen significant advances in understanding its underlying neurodegenerative mechanisms, r ...

2025

A NAC domain mutation (E83Q) unlocks the pathogenicity of human alpha-synuclein and recapitulates its pathological diversity

Hilal Lashuel, Anne-Laure Mahul Mellier, Sonia Donzelli, Ramanath Narayana Hegde, Pedro José Santana Ribeiro Magalhães

The alpha-synuclein mutation E83Q, the first in the NAC domain of the protein, was recently identified in a patient with dementia with Lewy bodies. We investigated the effects of this mutation on the aggregation of aSyn monomers and the structure, morpholo ...

AMER ASSOC ADVANCEMENT SCIENCE2022